Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $182.35M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.50M
Average 1.03M
Returns on capital
Inhibikase Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.9%
avg 9.7%
ROIC
-30.1%
avg 24.5%
ROA
-26.6%
avg -1588.7%
Analysis
ROA is currently the strongest return metric at -26.6% versus its period average of -1588.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Mark T. Iwicki | Chief Executive Officer & Director | USD 1.24M | 60 | 4.98M | 3.77% |
Christopher H. Cabell FACC | President, Head of Research & Development and Chief Medical Officer | USD 782.09K | 57 | — | — |
David John McIntyre | Chief Financial Officer | USD 668.29K | 56 | — | — |
John Adams | Chief Scientific Officer | — | — | — | — |
Chadwick J. Orevillo | Executive Vice President & Head of Development Operations | — | — | — | — |
Jeffrey J. Kagy | Chief Human Resources Officer | — | — | — | — |
Timothy J. Pigot | Chief Commercial & Strategy Officer | — | 55 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$3.00M
Sells
0
$0.00
Net Transaction Value
+$3.00M
Net buying
Most Active
Sands Capital Life Sciences Pulse Fund II, L.P.
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 21, 25Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. Direct | Buy | $3M$2,999,999.25 |
Summary
Insiders reported 1 buys worth $3.00M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $3.00M. Sands Capital Life Sciences Pulse Fund II, L.P. was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Inhibikase Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about IKT's management, answered from reported figures.
Who manages IKT?
Inhibikase Therapeutics, Inc. (IKT) lists 7 active executives. The top listed executive is John Adams, Chief Scientific Officer.
Are IKT insiders buying or selling?
Recent insider activity shows net buying of $73.97M.
Continue the stock analysis
Jump to another research area for this company.